A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer’s disease

ADRIENNE LITTLE,* RAYMOND LEVY,† PAZ CHUAQUI-KIDD,‡ DAVID HAND‡

From the Departments of Psychology,* the Section of Old Age Psychiatry† and the Biometrics Unit,‡ Institute of Psychiatry, and the Department of Psychological Medicine, Kings College Hospital,§ London, UK

SUMMARY The first long-term double-blind placebo controlled trial of high dose lecithin in senile dementia of the Alzheimer type is reported. Fifty one subjects were given 20–25 g/day of purified soya lecithin (containing 90% phosphatidyl plus lyso phosphatidyl choline) for six months and followed up for at least a further six months. Plasma choline levels were monitored throughout the treatment period. There were no differences between the placebo group and the lecithin group but there was an improvement in a subgroup of relatively poor compliers. These were older and had intermediate levels of plasma choline. It is suggested that the effects of lecithin are complex but that there may be a “therapeutic window” for the effects of lecithin in the condition and that this may be more evident in older patients.

Following the recognition of diminished levels of brain choline acetyltransferase in senile dementia of the Alzheimer type (SDAT)1—11 clinical approaches based on the “cholinergic hypothesis”12 have been developed. One of these has been the use of choline or the choline precursor lecithin.13—24 The matter has become more complicated as changes in other neurotransmitter systems have been reported25—37 and the general rationale of precursor loading has been questioned.38 In spite of these important theoretical issues, the therapeutic effectiveness of lecithin remains unknown. Clinical trials have reported disappointing results.39 However, these findings are difficult to interpret in view of the methodological shortcomings of most studies such as inadequate sample sizes, lack of controls, low doses of impure lecithin, often no placebo, no check on compliance and trials conducted over very brief periods with no follow-up.

The trial reported here has attempted to avoid these difficulties and was designed to test the hypothesis that high doses of lecithin might slow down the deterioration in relatively early cases of SDAT. To establish a differential rate of decline a double-blind placebo controlled design with relatively long treatment and follow-up periods was selected.

Materials and methods

Subjects

Potential subjects were obtained from various sources which included medical referrals to the hospital and other psychiatric services, direct referrals from the Alzheimer’s Disease Society and a sample of elderly community residents (drawn from a large general practice or from residential homes) who were classified as possibly demented on the basis of their score on a brief screening questionnaire administered by a nurse.40 To be included, subjects had to fulfill several criteria.

1 A clinical diagnosis of Alzheimer disease or SDAT established by a history of at least one year’s progressive deterioration in intellectual function for which all other causes including diabetes, hypertension or head injury could be excluded.

2 The absence of a history or physical signs of cerebro-vascular disease. This was established by a detailed history and examination of previous case notes. Any patient with an abrupt onset of dementia, a history suggestive of stroke or transient ischaemic attack, focal symptoms or focal signs was excluded, as were any patients with signs of hypertensive disease or with a diastolic blood pressure over 110 mm of Hg.

3 Performance was within a prescribed range on psychometric tests selected to monitor change. The difficulty level of these tests was set to be appropriate to the level of mild and moderate cases and the score such as to allow room either for improvement or for deterioration.
A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease

Table 1  Psychometric tests and factor scores

<table>
<thead>
<tr>
<th>Factor scores</th>
<th>Tests</th>
</tr>
</thead>
</table>
| FAC 1 (verbal learning and memory) | 1 Paired-Associate Learning Test (immediate and delayed)  
2 Verbal fluency  
3 Orientation questionnaire (All devised for the study) |
| FAC 2 (visuo-spatial and constructional) | 1 Kew Tests*  
2 Incomplete Letters*  
3 Cube Analysis98  
4 Digit Copy Test  
5 Colour Progressive Matrices  
6 1 PADL scales  
7 Physical Self Maintenance Scale  
8 3 Cube  
9 3 Instrumental Activities of Daily Living |
| FAC 3 (self care) | 1 3 Instrumental Activities of Daily Living |

(4) Subjects also had to be living with or near a reliable informant who could supervise their medication.

The initial assessment included a detailed medical and psychiatric history, and a neurological examination carried out by a psychiatrist with neurological experience, a standardised mental state examination for the elderly, and psychometric testing. Laboratory investigations included: blood urea and electrolytes, calcium, urate, cholestrol and total and free T4, routine haematological and serological examination. CT scans and EEG were performed on all hospital cases (one half of the total) but not on subjects obtained from the lists of general practitioners as approval for these procedures was not given.

Design

Subjects were allocated randomly to the lecithin or placebo group and monitored blindly during a 6 month period and reassessed following a 6 month drug-free period. The two groups were studied in parallel with no cross-over.

Preparations

Soya bean lecithin containing a minimum of 90% phosphatidyl plus lysophosphatidyl choline was supplied by Unilever Research Laboratories. This was prepared as a sweetened and flavoured emulsion in thick milk shake. The placebo consisted of a similar looking and tasting emulsion of "Flora" margarine to which propyl gallate and ascorbic acid were added as antioxidants. 100 ml of suspension containing 25 g of lecithin was the dose selected and this was divided into two or three equal doses (depending on the subjects' choice) taken at mealtimes under the supervision of an informant.

Compliance was assessed throughout the study from informants' reports and by measuring the amount of preparation consumed. The overall measure of compliance was made at the end of the treatment period, subjects being classified as good compliers if they had taken consistently 75% or more of the dose prescribed, and as poor compliers if they took less than this.

Free plasma choline levels were determined at baseline and after 1, 2, 4 and 6 months of treatment. The estimation was carried out on a plasma ultrafiltrate using a radioenzymatic assay.

Tests of orientation, learning and memory, perceptual and constructional skills and self care were administered. In view of the large number of tests used, it was determined that several hundred subjects would be required to analyse validly each test score as an individual dependent variable. Test scores were therefore reduced to three composite measures of different types of skill: orientation and verbal learning and memory (Factor 1) visuo-spatial and constructional skills (Factor 2) and self-care (Factor 3). These measures were derived by classifying tests according to content and extracting single measures of these by factor analysis (using IMAGE factoring). Factor 1 (FAC 1) was assessed at baseline and after 1, 2, 4 and 6 months on treatment and after 6 months follow-up. Factors 2 (FAC 2) and 3 (FAC 3) were assessed at baseline, after 6 months treatment and after 6 months follow-up. It should be pointed out that on FAC 1 and 3 the higher the score the higher the ability whereas on FAC 2 high scores indicate impairment (table 1).

Statistical treatment

Simple comparisons between groups for individual variables were made using univariate analysis of variance. Multivariate techniques were used to compare groups overall on several variables at baseline and to examine differences in the pattern of changes shown during the treatment

Table 2  Baseline data for placebo and lecithin groups*

| Variable | Placebo group  
|-----------|----------------|
| N = 171 | Lecithin group  
| N = 187 | Univariate F (df 1,33) |
| 1 Age at start of trial | 74.8 ± 12.52 | 76.8 ± 9.27 | 1 |
| 2 Duration of illness (years) | 3.47 ± 2.07 | 4.00 ± 2.22 | 1 |
| 3 Neuro-psychiatric battery  
—cortical dysfunction | 14.74 ± 8.45 | 10.97 ± 8.04 | 1.83 |
| —affective symptoms | 20.35 ± 14.11 | 15.28 ± 9.63 | 1.56 |
| —cognitive impairment | 14.41 ± 7.40 | 11.33 ± 5.37 | 2.00 |
| 4 Plasma choline value (nmol/ml) | 12.71 ± 5.05 | 12.33 ± 3.66 | 1 |
| Psychometric test performance  
—FAC 1 (ability) | 50.43 ± 24.05 | 47.88 ± 18.56 | 1 |
| —FAC 2 (impairment) | 7.39 ± 6.57 | 1.99 ± 7.32 | 5.25† |
| —FAC 3 (ability) | 25.20 ± 7.05 | 29.41 ± 6.40 | 3.60 |

*Results given as mean ± standard deviation
†N refers to subjects with complete data for all nine variables included in the multivariate analysis
‡p < 0.05
period on plasma choline levels and FAC 1. These changes were described by polynomial analyses of trend which examine and compare the shapes of curves. Five data points were considered (baseline and after 1, 2, 4 and 6 months on treatment) and the linear (straight line), quadratic (one reversal of trend, or "bend"), cubic (two reversals of trend or "bends") and quartic (three reversals of trend or "bends") components of the changes shown during this period calculated and compared for the groups.

Results

Sample

Potential subjects numbering 296 were considered of whom 82 fulfilled the inclusion criteria. Nineteen refused to participate, 12 withdrew during treatment and three died during follow-up, leaving 51 subjects who completed treatment (26 on placebo, 25 on lecithin) and 48 who completed the full year (24 in each group). Overall the two groups were comparable at baseline (table 2) and there were no differences in sex or source of referral. However the placebo group was significantly more impaired on FAC 2 (Univariate F = 5.25; df 1,33; p < 0.05) and there was considerable heterogeneity within both groups for most measures.

Compliance and tolerance

Many subjects found the six months treatment period long and the preparations unpalatable. Only a few reported side-effects (17 of the 63 who started on the trial) complaining of gastrointestinal discomfort (either diarrhea or a feeling of excessive fullness in the abdomen) or nausea which disappeared in all cases when the dose was reduced to 20 g. The weight gain reported in previous studies using impure lecithin was not a problem. There were more drop-outs from the lecithin group than from the placebo group (nine compared with three), more complaints of side-effects (14 compared with three) and more poor lecithin compliers (eight compared with four). Good and poor lecithin compliers were compared at baseline (table 3). Overall there were no significant differences (Multivariate F = 1.46; df 9,8; N.S.) but the poor compliers were significantly older (Univariate F = 5.63; df 1,16; p < 0.05).

Plasma choline values

As predicted, lecithin significantly raised plasma choline values throughout the six months of treatment (Drug × Time interaction; Multivariate F =

### Table 3 Baseline data: good and poor compliers on lecithin

<table>
<thead>
<tr>
<th>Variable</th>
<th>Poor compliers* N = 67</th>
<th>Good Compliers* N = 121</th>
<th>Univariate F (df 1,16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Age at start of trial</td>
<td>83.33 ± 5.96</td>
<td>73.58 ± 9.06</td>
<td>5.63†</td>
</tr>
<tr>
<td>2 Duration of illness (years)</td>
<td>4.50 ± 1.87</td>
<td>3.75 ± 2.42</td>
<td>1</td>
</tr>
<tr>
<td>3 Neuro-psychiatric examination scores</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>—cortical dysfunction</td>
<td>13.16 ± 10.73</td>
<td>9.87 ± 6.61</td>
<td>1</td>
</tr>
<tr>
<td>—affective symptoms</td>
<td>18.00 ± 10.75</td>
<td>13.92 ± 9.21</td>
<td>1</td>
</tr>
<tr>
<td>—cognitive impairment</td>
<td>9.00 ± 5.14</td>
<td>12.50 ± 5.30</td>
<td>1.78</td>
</tr>
<tr>
<td>4 Plasma choline value (nmol/ml)</td>
<td>12.83 ± 3.49</td>
<td>12.08 ± 3.87</td>
<td>1</td>
</tr>
<tr>
<td>5 Psychometric test performance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>—FAC 1 (ability)</td>
<td>48.28 ± 17.65</td>
<td>47.68 ± 20.20</td>
<td>1</td>
</tr>
<tr>
<td>—FAC 2 (impairment)</td>
<td>2.63 ± 5.85</td>
<td>1.67 ± 8.17</td>
<td>1</td>
</tr>
<tr>
<td>—FAC 3 (ability)</td>
<td>26.11 ± 7.06</td>
<td>31.05 ± 4.99</td>
<td>2.99</td>
</tr>
</tbody>
</table>

*Results given as mean ± standard deviation
†N refers to subjects with complete data for all nine variables included in the multivariate analysis
$p < 0.05$
A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease

Fig 3  Factor 1 scores (learning & memory) in three groups of patients

12.11; df 4.32; p < 0.001) (fig 1). This elevation of choline value was a function of compliance to lecithin (Drug × Time × Compliance interaction; Multivariate F = 2.74; df 4.30; p < 0.05). Poor compliers showed elevated levels of choline values relative to the placebo group but this increase was almost half that shown by the good compliers and was maintained for the first four months of treatment only (fig 2).

Fig 4  Factor 2 scores (visuo-spatial & constructional) in three groups of patients

Changes in test performance
When the two main groups (placebo and lecithin) were compared there were no significant differences on any of the three measures of change during treatment or follow-up. However in view of the relatively large number of poor compliers and the general impression that some subjects had responded better than others, a separate comparison of the good compliers, the poor compliers and the placebo group was carried out. Mean scores for these three groups on the three psychometric measures are shown in figs 3, 4 and 5.

Against expectations poor compliers appear to do best and improved during the treatment period on FAC 1 and FAC 3. Good compliers and placebo subjects show similar, slight changes during this period. The changes shown by poor compliers were compared with those shown by good compliers and by the placebo group.

For FAC 1 the overall multivariate comparisons of these changes did not quite reach acceptable levels of significance. However, for both comparisons the quadratic component of these changes was significant suggesting differences in the pattern of changes shown during treatment (table 4).

From fig 3 it seems that whereas good compliers

Table 4  Statistical analysis of comparison between placebo group, poor compliers and good compliers

<table>
<thead>
<tr>
<th>Multivariate Comparisons of Changes (Group × Time Interaction)</th>
<th>Poor compliers (N = 6) vs Placebo subjects (N = 24)*</th>
<th>Good compliers (N = 12) vs Poor compliers (N = 6)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Univariate Comparisons of Polynomial Components of Changes:</td>
<td>F = 2.4; df 4.26; p &lt; 0.08</td>
<td>F = 2.0; df 4.14; p &lt; 0.16</td>
</tr>
<tr>
<td>Step-down Test:</td>
<td>F = 1.29</td>
<td>F = 0.84</td>
</tr>
<tr>
<td>Linear</td>
<td>F = 0.01</td>
<td>F = 0.32</td>
</tr>
<tr>
<td>Quadratic</td>
<td>F = 4.93; p &lt; 0.03</td>
<td>F = 6.25; p &lt; 0.02</td>
</tr>
<tr>
<td>Cubic</td>
<td>F = 3.39</td>
<td>F = 0.84</td>
</tr>
<tr>
<td>Quartic</td>
<td>F = 0.75</td>
<td>F = 0.43</td>
</tr>
</tbody>
</table>

*N refers to subjects with complete data for FAC 1
and placebo subjects showed slight fluctuations in performance during the 6 month treatment period the scores of poor compliers improved consistently during the first four months on lecithin but then fell to baseline levels at 6 months. For FAC 2 no group differences were significant. For FAC 3, the changes shown by good and poor compliers during treatment were significantly different (univariate F = 6.64; df. 1,20; p < 0.01) but the differences between poor compliers and placebo subjects just failed to reach significance (univariate F = 3.80; df. 1,26; p < 0.06). Whereas good compliers and placebo subjects showed slight changes during the treatment period there was a marked improvement in the performance of poor compliers (fig 5).

Since there was a significant difference in age between good and poor compliers and between poor compliers and placebo, differences between the groups were re-examined using analysis of covariance to control for age. Similar results were found. However the analysis of trend for FAC 1 now failed to reach significance but significant group differences were found consistently for FAC 3 when comparing good with poor compliers (Univariate F = 7.70; df 1.18; p < 0.01) and poor compliers with placebo subjects (Univariate F = 4.64; df 1.24; p < 0.05).

Discussion

The effects of lecithin on psychometric test performance were complex and unpredicted. Thus, although as a whole there were no significant differences between the lecithin and placebo groups, when other factors such as compliance, plasma choline levels and age were taken into account interesting trends emerged. We had expected that good compliers would fare better. In fact the reverse was the case. In so far as a “responder” subgroup might be identified it was the relatively poor compliers who did best. They showed moderate improvement in FAC 1 (orientation, learning and memory) at four months, a time when their plasma choline level was just below twice the baseline value. This improvement was not maintained at six months by which time plasma choline had returned to baseline level. We suspect that this is because the patients had by then stopped taking any lecithin at all. The possibility that the drop in plasma choline in the poor-complier group might be due to enzyme induction cannot be excluded. A decline in plasma choline on an apparently fixed dose of lecithin has previously been reported but it should be noted that no such decline was found in the good complier group and the time course is probably inconsistent with the possibility of enzyme induction.

On FAC 3 (activities of daily living) there was a substantial improvement at six months and this was maintained after six months follow-up. Unfortunately since the assessments concerned were not carried out at four months no direct comparison with the transient improvements in memory and orientation can be carried out.

FAC 2 (visuo-spatial and constructional skills) showed a very slight decline in all three groups throughout the period of treatment and follow-up period.

A question then arises as to the comparability between the poor-compliers and the rest. It will be noted that they were older and that when the effects of age were controlled for the differences in FAC scores were no longer significant but those for FAC 3 became greater.

Rossor et al have shown that older patients with Alzheimer’s disease are more likely to have a pure cholinergic deficit and it is conceivable that at least part of the difference between poor compliers and good-compliers might be related to age. However this would only account for the effects in orientation, learning and memory but not for those on self-care which remained significant when age was controlled for. There remains the possibility that the groups might have differed in some other as yet unidentified feature which might have differentially affected the course of the disease in the poor-complier group.

The final explanation is that there might be a therapeutically optimal dose of lecithin which poor compliers may have received by chance. A similar “therapeutic window” has been described for other cholinergic agonists such as physostigmine and it is conceivable that a plasma-choline level around twice the baseline value should be aimed at.

The effects of lecithin on the course of SDAT are therefore complex and it is certainly premature to abandon attempts to establish when and how it should be used. Although caution is required in the interpretation of the results the present study suggests that some subjects may respond to moderate doses. The present data do not allow us to conclude whether this applies to all patients with the condition. The effects seem to take several months to develop and they may be restricted to changes in certain important skills. The results clearly require replication and future studies should be directed at trying to disentangle the effects of age, plasma choline levels and other factors.

We thank the numerous colleagues who referred cases for the trial; Mrs Margaret Reith and Mrs Lynne Johnston for their invaluable help in screening subjects and carrying out numerous assessments;
A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease

Mr Basil Ashkenasy and the staff of the pharmacy at the Maudsley Hospital for mixing and storing the preparations; Dr Roger Marchbanks for advice about the choline assays; Mrs Jean Perkins and Mrs Nadine Morgan for secretarial assistance and the staff and residents of numerous old people's homes for their forbearance. The lecithin was supplied by Unilever Research and the work was supported by the Medical Research Council.

References


A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer’s disease.

A Little, R Levy, P Chuaqui-Kidd and D Hand

*J Neurol Neurosurg Psychiatry* 1985 48: 736-742
doi: 10.1136/jnnp.48.8.736

Updated information and services can be found at:
http://jnnp.bmj.com/content/48/8/736

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/